+
diff --git a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx
index 2d3f0b033..35d4ae743 100644
--- a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx
+++ b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx
@@ -83,6 +83,7 @@ export const DRUGS_CURRENTLY_IN_ONCOKB = `Drug(s) currently in ${ONCOKB_TM}`;
export const DRUGS_REMOVED_FROM_ONCOKB = `Drug(s) removed from ${ONCOKB_TM}`;
export const DRUGS_DEMOTED_IN_ONCOKB = `Drug(s) demoted in ${ONCOKB_TM}`;
export const DRUGS_PROMOTED_IN_ONCOKB = `Drug(s) promoted in ${ONCOKB_TM}`;
+export const DRUGS_CHANGED_IN_ONCOKB = `Drug(s) changed in ${ONCOKB_TM}`;
export const DRUGS_ASSOCIATED_WITH_CURRENT_LEVEL =
'Drug(s) Associated with the Current Level';
export const UPDATED_SENSITIVITY_LEVEL = 'Updated Sensitivity Level';
@@ -141,6 +142,16 @@ export const CHANGED_ANNOTATION_DRUG_COLUMNS = [
{ name: EVIDENCE },
];
+export const CHANGED_ANNOTATION_DRUG_SAME_HIGHEST_LEVEL_COLUMNS = [
+ { name: LEVEL },
+ { name: GENE },
+ { name: MUTATION },
+ { name: CANCER_TYPE },
+ { name: DRUGS_CURRENTLY_IN_ONCOKB },
+ { name: DRUGS_CHANGED_IN_ONCOKB },
+ { name: EVIDENCE },
+];
+
export const CHANGED_ANNOTATION_ADDITIONAL_DRUG_SAME_LEVEL_COLUMNS = [
{ name: GENE },
{ name: MUTATION },
@@ -250,6 +261,167 @@ const EVIDENCE_COLUMN_SEPARATOR = '; ';
// https://stackoverflow.com/questions/41947168/is-it-possible-to-use-keyof-operator-on-literals-instead-of-interfaces
export const NEWS_BY_DATE: { [date: string]: NewsData } = {
+ '07022024': {
+ priorityNews: [
+
+ Release of{' '}
+
+ {ONCOKB_TM} SOP v4.1
+
+ ,
+
+ Updated HUGO symbol for gene SLC9A3R1 to{' '}
+
+ ,
+ ],
+ changedAnnotations: [
+ {
+ columnHeaderType:
+ AnnotationColumnHeaderType.PROMOTION_TUMOR_TYPE_SPECIFIC_EVIDENCE,
+ content: [
+ [
+ 'KRAS',
+ 'G12C',
+ 'Colorectal Cancer',
+
+
+ {DRUGS_CURRENTLY_IN_ONCOKB}:
+
+
Sensitivity
+
+ Adagrasib + Cetuximab, Adagrasib + Panitumumab, Sotorasib +
+ Cetuximab, Sotorasib + Panitumumab (Level 2)
+
+
+
Resistance
+
+ Tucatinib + Trastuzumab, Cetuximab, Panitumumab (Level R1)
+
+
+
+ {DRUGS_PROMOTED_IN_ONCOKB}:
+
+
Adagrasib + Cetuximab (Level 1)
+
,
+ '2',
+ '1',
+
+
+
+ ,
+ ],
+ [
+ 'KRAS',
+ 'G12C',
+ 'Biliary Tract Cancer',
+ 'Adagrasib',
+ '3A',
+ '2',
+
+
+ Inclusion in NCCN Biliary Tract Cancer Guidelines V2.2024
+
+
+ ,
+ ],
+ ],
+ },
+ {
+ columnHeaderType: AnnotationColumnHeaderType.ADDITIONAL_SAME_LEVEL_DRUG,
+ title: `Updated therapeutic implications - Addition of therapy(s) associated with a tumor type-specific leveled alteration(s) (without changing the alteration's highest level of evidence)`,
+ content: [
+ [
+ 'EGFR',
+ 'Exon 19 in-frame deletion, L858R',
+ 'Non-Small Cell Lung Cancer',
+ '1',
+ 'Erlotinib, Afatinib, Gefitinib, Dacomitinib, Erlotinib + Ramucirumab, Osimertinib (Level 1); Patritumab Deruxtecan (Level 3A)',
+ 'Osimertinib + Chemotherapy (Level 1); Amivantamab + Chemotherapy (Level 2); Amivantamab + Lazertinib (Level 3A)',
+
+
+
+ Inclusion of Amivantamab + Chemotherapy in NCCN Non-Small Cell
+ Lung Cancer Guidelines V5.2024
+
+
+ ,
+ ],
+ [
+ 'EGFR',
+ 'S768I, L861Q, G719X',
+ 'Non-Small Cell Lung Cancer',
+ '1',
+ 'Afatinib (Level 1); Osimertinib (Level 2); Patritumab Deruxtecan (Level 3A)',
+ 'Erlotinib, Gefitinib, Dacomitinib, Amivantamab + Chemotherapy (Level 2); Amivantamab + Lazertinib (Level 3A)',
+
+
+ Inclusion of Erlotinib, Gefitinib, Dacomitinib and Amivantamab +
+ Chemotherapy in NCCN Non-Small Cell Lung Cancer Guidelines
+ V5.2024
+
+
+
+ ,
+ ],
+ [
+ 'ERBB2',
+ 'Amplification',
+ 'Biliary Tract Cancer',
+ '2',
+ 'Trastuzumab + Pertuzumab',
+ 'Tucatinib + Trastuzumab (Level 2)',
+
+
+ Inclusion in NCCN Biliary Tract Cancer Guidelines V2.2024
+
+
+ ,
+ ],
+ ],
+ },
+ {
+ columnHeaderType:
+ AnnotationColumnHeaderType.DRUG_UPDATE_SAME_HIGHEST_LEVEL,
+ content: [
+ [
+ '1',
+ 'NTRK1, NTRK2, NTRK3',
+ 'Fusions',
+ 'All Solid Tumors',
+ 'Larotrectinib, Entrectinib (Level 1); Repotrectinib (Level 3A)',
+ 'Repotrectinib (Level 1)',
+
+ {' '}
+
+ ,
+ ],
+ ],
+ },
+ ],
+ newlyAddedGenes: ['LMNA', 'PRCC', 'UBA1', 'UBTF', 'RIOK2'],
+ },
'06042024': {
priorityNews: [
@@ -283,7 +455,10 @@ export const NEWS_BY_DATE: { [date: string]: NewsData } = {
Inclusion in Colon Cancer NCCN Guidelines V2.2024 and in Small
Bowel Adenocarcinoma NCCN Guidelines V3.2024
-
+
-
+
= props => {
'https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications'
}
>
- Content current as of 4/23/2024
+ Content current as of 6/19/2024
diff --git a/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.json b/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.json
index 4e934248e..835f78bd8 100644
--- a/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.json
+++ b/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.json
@@ -2198,5 +2198,25 @@
"targetedTx": "Y",
"pxTx": "Y",
"ngsTest": "Y"
+ },
+ {
+ "year": "2024",
+ "tx": "Tarlatamab",
+ "biomarker": "",
+ "agentClass": "Bispecific T-cell engager",
+ "drugTarget": "Bispecific DLL3-directed CD3 T-cell engager",
+ "targetedTx": "Y",
+ "pxTx": "N",
+ "ngsTest": "NA"
+ },
+ {
+ "year": "2024",
+ "tx": "Imetelstat",
+ "biomarker": "",
+ "agentClass": "Telomerase inhibitor",
+ "drugTarget": "Telomerase template antagonist",
+ "targetedTx": "Y",
+ "pxTx": "N",
+ "ngsTest": "NA"
}
]
diff --git a/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.xlsx b/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.xlsx
index f8b4d3ba8..00ec21998 100644
Binary files a/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.xlsx and b/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.xlsx differ
diff --git a/src/main/webapp/content/images/oncokb_summary.png b/src/main/webapp/content/images/oncokb_summary.png
index 772e12f3e..625a88721 100644
Binary files a/src/main/webapp/content/images/oncokb_summary.png and b/src/main/webapp/content/images/oncokb_summary.png differ
diff --git a/src/main/webapp/index.html b/src/main/webapp/index.html
index cf8d940c6..3a1d849e5 100644
--- a/src/main/webapp/index.html
+++ b/src/main/webapp/index.html
@@ -15,7 +15,7 @@
-
+
@@ -23,7 +23,7 @@
-
+